Th e original name for serotonin (5-hydroxytryptamine; 5-HT) was enteramine because it was initially discovered in the gastrointestinal (GI) tract, and the gut is the major source of 5-HT in vertebrates ( 1 ). A subset of enteroendocrine cells called enterochromaffi n (EC) cells use the enzyme tryptophan hydroxylase-1 (TpH-1) to synthesize 5-HT, and these cells release 5-HT from their basal surface into the insterstitial space of the lamina propria in response to chemical and mechanical stimuli ( 2,3 ). Once released into lamina propria, 5-HT can activate receptors on nearby intrinsic nerve fi bers to stimulate motility, secretory, and vasodilatory refl exes, as well as receptors on extrinsic aff erent nerves to send signals to the brain and spinal cord. Serotonergic signaling in the lamina propria is terminated by removal from the interstitial space via serotonin-selective reuptake transporter (SERT), which is expressed by epithelial cells. Th e 5-HT that is not transported into epithelial cells enters the blood stream where is it taken up via SERT into platelets, which, when activated, release 5-HT to assist in hemostasis.
INTRODUCTION
Th e original name for serotonin (5-hydroxytryptamine; 5-HT) was enteramine because it was initially discovered in the gastrointestinal (GI) tract, and the gut is the major source of 5-HT in vertebrates ( 1 ) . A subset of enteroendocrine cells called enterochromaffi n (EC) cells use the enzyme tryptophan hydroxylase-1 (TpH-1) to synthesize 5-HT, and these cells release 5-HT from their basal surface into the insterstitial space of the lamina propria in response to chemical and mechanical stimuli ( 2, 3 ) . Once released into lamina propria, 5-HT can activate receptors on nearby intrinsic nerve fi bers to stimulate motility, secretory, and vasodilatory refl exes, as well as receptors on extrinsic aff erent nerves to send signals to the brain and spinal cord. Serotonergic signaling in the lamina propria is terminated by removal from the interstitial space via serotonin-selective reuptake transporter (SERT), which is expressed by epithelial cells. Th e 5-HT that is not transported into epithelial cells enters the blood stream where is it taken up via SERT into platelets, which, when activated, release 5-HT to assist in hemostasis.
Given the importance of 5-HT in the regulation of gut functions and in sensory signaling from the gut, a number of studies have been conducted with humans and animal models to test whether 5-HT signaling is altered in disorders associated with changes in gut function and sensation. While a clear pattern has not yet emerged, most of these studies have detected changes in various elements of gut serotoninergic physiology, including 5-HT FUNCTIONAL GI DISORDERS content, numbers of EC cells, TpH-1 expression, mucosal 5-HT release, SERT expression, and postprandial circulating 5-HT levels ( 4, 5 ) . Moreover, it is likely that alterations in 5-HT signaling do exist in functional GI disorders and / or in the presence of infl ammation; however, the pattern of changes and the cause-and-eff ect relationship of these changes with regard to diarrhea, constipation, and / or visceral hypersensitivity have not been resolved.
Chronic constipation (CC) is a condition in which pain and discomfort are not primary symptoms. Multiple mechanisms are known to aff ect colonic motility; from opiate receptor activation, to neurostructural abnormalities, as well as alterations in gut neurochemicals, but it is unclear whether altered serotonin signaling plays a role in its ' causality. Th is is a very common disorder aff ecting up to 19 % of the US population ( 6 ) , and it has a high degree of symptom overlap with the constipation-predominant irritable bowel syndrome (IBS-C). In fact, it is possible that CC and IBS-C are actually the same disorder with diff erent individuals situated at diff erent locations along a continuum of pain and discomfort ( 7 ) .
Th e purpose of this investigation was to test the hypothesis that 5-HT synthesis, release, and / or SERT transcript levels are altered in the rectal mucosa of individuals with CC in a manner similar to the changes previously reported in IBS-C. To accomplish this, rectal biopsy samples were obtained from individuals with CC and healthy controls, and levels of 5-HT content, EC cell numbers, 5-HT release, and TpH-1 and SERT transcript levels were compared. We also tested the hypothesis that these elements of 5-HT signaling are not altered in tissue from individuals with opiateinduced constipation (OIC), to address the issue of whether constipation itself can lead to compensatory alterations 5-HT availability in the intestinal mucosa.
METHODS

Human tissue acquisition
Human colonic tissue samples were obtained from individuals who met the diagnostic criteria for one of the following groups: healthy controls, CC, individuals undergoing opiate therapy with constipation, and those undergoing opiate therapy without constipation. Th e University of Vermont Institutional Review Board approved all aspects of this study.
Subjects with CC were recruited from the clinical universitybased gastroenterology colorectal surgery practices (University of Vermont College of Medicine in association with Fletcher Allen Health Care) or through local printed advertisement. Volunteers with OIC were recruited via posters put in the local pain management clinic and methadone clinic. A questionnaire was administered by trained healthcare providers to identify subjects who met the criteria for CC or OIC.
Th e Rome II criteria were used to identify subjects included in the CC group. Th ese subjects reported constipation for at least 12 weeks in the previous year. At least 25 % of the time, they experienced two or more of the following symptoms: < 3 bowel movements / week, straining with defecation, hard and / or lumpy stools, sensation of incomplete evacuation, sensation of anorectal obstruction, and use of manual maneuvers to assist with defecation. Patients who met these criteria diff er from those with IBS-C in that abdominal pain or discomfort was not a prominent clinical feature. None of these patients were taking medications that could cause constipation as a primary or secondary eff ect.
Individuals in the opiate therapy groups had been taking these compounds for at least 3 months, but most had been using opiate analgesics for at least 2 years. Volunteers with OIC all experienced < 3 bowel movements / week. Th ey were also screened using the same questionnaires as noted above to rule out concurrent diagnoses of IBS, other GI disorders, or use of other medications that could cause constipation as a primary or secondary eff ect. Th e demographic makeup of the OIC population is listed in Table 1 .
Healthy controls provided consent at the time of presenting for scheduled screening colonoscopy. Following sodium phosphate preparation fi ve rectal biopsy samples were obtained in succession from each participant using high-capacity biopsy forceps, and each sample was immediately processed by one of the procedures listed 
Immunohistochemistry
Biopsies were fi xed in a 10 % formalin solution and standard techniques were used to prepare each biopsy sample for immunoreactive staining, as previously described ( 8 ) . Th e primary antiserum used to identify EC cells was mouse-conjugated anti-5-HT (1:500; Dako Diagnostica, Carpinteria, CA) . Th e secondary antibody used was goat anti-mouse AMCA (1:250; Jackson ImmunoResearch, West Grove, PA) . All of the sections were then incubated with a 1:30,000 dilution of the nucleic acid stain, yo-yo (Molecular Probes, Eugene, OR). One slide from each biopsy was stained with hematoxylin and eosin to evaluate the degree of infl ammation present in the biopsy specimen.
Epithelial cells were quantifi ed by counting the number of stained nuclei of epithelial cells for a given length of colon, including at least three crypts, and quantifi ed as the number of epithelial cells per crypt. 5-HT-containing epithelial cells were counted and normalized as functions of the number of EC cells per colonic gland, and as the proportion of epithelial cells that were EC cells. Th ese determinations were made at a magnifi cation of 400 × from three random locations in each transverse section, while taking care to ensure that the area contained intact colonic glands.
Histological assessment
Hematoxylin and eosin-stained tissue sections from each individual in the study were blindly assigned an infl ammatory activity score, on a scale of 0 -3, by an experienced GI pathologist. Th e scoring system was as follows: 0, normal numbers of infl ammatory cells in the lamina propria, with no active infl ammation; 1, normal numbers of infl ammatory cells in the lamina propria with rare neutrophils within the crypt epithelium or minimally increased numbers of infl ammatory cells in the lamina propria and no neutrophils within the crypt epithelium; 2, increased numbers of infl ammatory cells in the lamina propria and mild active infl ammation; and 3, increased numbers of infl ammatory cells in the lamina propria and moderate / severe active infl ammation. Scores of 0 and 1 were considered to be within the normal range. Scores of 2 or 3 were considered to be histopathologically infl amed and usually refl ected an inactive / mildly active colitis or a moderately / severely active chronic colitis, respectively. Individual samples that were evaluated to have an infl ammatory score of 2 or higher were to be eliminated from further analysis and would not be included in the results. All of the sections evaluated in this study had scores of 0 or 1; therefore, none of the samples were excluded for infl ammation.
Measuring 5-HT content and release
Th e 5-HT content in homogenized biopsy specimens, or released into buff er solution from each individual, was analyzed with an enzyme immunoassay kit according to the manufacturer ' s instructions (Beckman Coulter, Fullerton, CA). Two biopsy specimens from each individual were used to assess 5-HT release. Specimens were maintained at 37 ° C under one of two experimental conditions: " Basal Release " : 5 min in 500 ml of a 10 mM HEPES buff er solution at 37 ° C (pH 7.4) (Sigma Chemical, St Louis, MO) or " Stimulated Release " : 2 min in 500 ml of HEPES buff er at 37 ° C, followed by 3-min mild agitation on a vortex machine. Aft er the fi ve minutes of the above procedures, 400 ml of solution was removed and placed in a new Eppendorf tube. 5-HT released into the bathing solution was subsequently measured by the same enzyme immunoassay described above.
Measurement of mRNA encoding TpH-1 and SERT
Transcripts encoding TpH-1 and SERT were quantifi ed by realtime reverse transcription -PCR (RT-PCR). RNA was extracted from the samples using RNeasy mini-kits (Qiagen Sciences, Valencia, CA) and cDNA was generated by reverse transcription (Promega, Madison, WI). For real-time PCR, Fast Universal PCR Master Mix and validated fl uorogenic TaqMan Gene Expression Assays-on-Demand for TpH-1 (Hs00188220_m1), SERT (Hs00169010_m1), phosphomannomutase-1 (PMM1; Hs00160195_m1), and hypoxanthine -guanine phosphoribosyltransferase (HPRT; Hs99999909_m1) were used in conjunction with an Applied Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). Data were calculated using the relative standard curve method and the level of SERT or TpH-1 RNA in each sample was normalized to PMM1 and HPRT. Amplifi cation effi ciencies ranged from 98.9 to 100.4 % . PMM1 and HPRT transcript levels in the populations studied were comparable ( P > 0.05). Here we present data normalized to PMM1 as the span of cycle thresholds was tighter for this gene than for HPRT.
Data analysis
Th e data presented represent the means ± s.e.m. for n subjects. Statistical analyses were performed using the Prism soft ware (version 4; GraphPad Soft ware, San Diego, CA). Comparisons between two groups were made parametrically by Student ' s t -test to compare control vs. CC data or by one-way analysis of variance with Tukey post hoc test to compare values from healthy subjects and individuals undergoing opiate therapy with or without constipation. Only diff erences with P < 0.05 were considered signifi cant.
RESULTS
5-HT content
Enzyme immunoassay was used to determine the amount of 5-HT in individual biopsy specimens. As demonstrated in Figure 1a , the 5-HT content of the samples from CC subjects was signifi cantly higher than that of healthy subjects. However, no signifi cant differences in 5-HT content were detected among samples from healthy controls and samples from individuals undergoing opiate therapy with or without constipation ( Figure 1b ) .
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TpH-1 RNA levels
Two isoforms exist for TpH, which is the rate-limiting enzyme for 5-HT synthesis ( 9 ) . Isoform-1, or TpH-1, is used by EC cells in the intestinal mucosa, whereas TpH-2 is expressed by neurons in the central and peripheral nervous systems. We therefore used real-time quantitative RT-PCR to evaluate the TpH-1 transcript levels in RNA extracted from biopsy samples. Data were evaluated relative to transcript levels of PMM1, which did not diff er among the populations investigated in this study. Consistent with the fi nding of higher 5-HT content samples from individuals with CC as compared with that in healthy control samples, TpH-1 RNA levels were higher in samples from CC subjects than in samples from healthy control volunteers ( Figure 1c ) . No diff erences were detected among the TpH-1 RNA levels from the two opiate therapy groups and healthy controls ( Figure 1d ). Comparable fi ndings were obtained when HPRT was used as endogenous control. We chose to present data relative to PMM1 because the cycle thresholds were tighter among the samples for PMM1 than for HPRT.
EC cell numbers
Th e data described above indicate that 5-HT synthesis and content are increased in the mucosa of individuals with CC, but that these elements of 5-HT signaling are unchanged in OIC. As EC cells are the predominant source of 5-HT in the mucosal layer of the gut, antiserum directed against 5-HT was used to label and quantify EC cells in the colonic glands. No diff erences were detected in either the CC group or the opiate treatment group as compared with healthy controls with regard to number of EC cells per colonic gland or the proportion of epithelial cells that were EC cells ( Figure 2 ).
5-HT release
Serotonin is released in the intestinal mucosa under basal conditions, and at higher levels in response to mechanical stimulation ( 8, 10, 11 ) . In this study, enzyme immunoassay was used to evaluate 5-HT released from mucosal biopsy specimens into HEPES buff er in samples that were simply heated to 37 ° C and in samples that were mechanically stimulated for 3 min by mild vibration using a vortex machine. Histological evaluation of sections that underwent mechanical stimulation confi rmed that the tissue remained intact following this procedure.
Under both basal and stimulated conditions, 5-HT concentrations were higher in buff er that contained CC biopsy samples than those that contained healthy control samples ( Figures 3a and b ) . No diff erences were detected in 5-HT concentrations in buff er samples from opiate vs. control groups under basal or stimulated conditions ( Figures 3c and d ) .
SERT RNA levels
In addition to content and release, another factor that can infl uence 5-HT availability in the lamina propria of the intestinal mucosa is the capacity to remove 5-HT from the interstitial space. Intestinal epithelial cells express the SERT, and the amount of SERT expressed by intestinal epithelial cells can be altered under certain conditions, including infl ammation ( 8, 12 ) , celiac disease ( 13 ) , and IBS ( 8 ) . Th erefore, real-time quantitative RT-PCR was used to assess whether SERT production might be diff erent in the 
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of 5-HT signaling in the rectal mucosa of individuals with OIC to investigate the cause-and-eff ect relationship of altered 5-HT signaling, by using a condition in which the cause of disordered function is understood. Th e fi ndings of this study are schematically summarized in Figure 5 . Data from the current study indicate that 5-HT availability in the lamina propria of the colonic mucosa is increased in CC. We found that 5-HT content was signifi cantly higher in CC samples as compared with that in rectal biopsy specimens from healthy controls. Th is is consistent with the fi ndings of Lincoln et al. ( 14 ) who reported that 5-HT levels were signifi cantly elevated in the sigmoid colon in severe idiopathic constipation. Additional lines of evidence from this study that support increased 5-HT availability in CC include increased levels of TpH-1 RNA, the rate-limiting biosynthetic enzyme used by EC cells, and increased 5-HT release under both basal and stimulated conditions in mucosal intestinal mucosa of individuals with CC and / or OIC as compared with that of healthy controls. No diff erences in SERT RNA levels were detected in samples from CC subjects or the opiate treatment groups as compared with samples from healthy controls ( Figure 4 ).
DISCUSSION
Release of 5-HT from EC cells in the intestinal mucosa is one of the principal triggers of motor and sensory refl ex activity in the gut, as well as communication from the gut to the central nervous system ( 3 ) . Studies of a number of infl ammatory and functional disorders indicate that alterations in various aspects of mucosal 5-HT are features of these conditions ( 4, 5 ) . One aim of this investigation was to determine whether CC is associated with alterations in mucosal 5-HT signaling. Furthermore, we evaluated the status 
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a decreased capacity to remove 5-HT from the interstitial space once it is released.
Th e fi ndings reported here do not provide direct evidence for a causal relationship between serotonin signaling and constipation in CC; however, it is quite possible that an increase in synthesis and release of 5-HT in the mucosa could contribute to constipation in CC through receptor desensitization. In vitro studies have demonstrated that exposure of guinea pig distal colon preparations to desensitizing concentrations of 5-HT or to the SERT inhibitor, fl uoxetine, decrease the rate of propulsive motility ( 22 ) . Furthermore, in the central nervous system, 5-HT receptor binding is downregulated in response to administration of serotoninselective reuptake inhibitors ( 23, 24 ) . Despite in vitro evidence of serotonin-induced motility alterations, it is diffi cult to determine whether the 5-HT alterations measured in bowel disorders are the cause or result of motility changes in vivo . Th is study attempted to delineate cause and eff ect by taking mucosal samples from subjects experiencing constipation with a known chemical cause, narcotic use, as well as those taking narcotic pain medications who were not constipated. If the colonic samples from those with OIC showed alterations in 5-HT similar to those with CC, then this would suggest that the 5-HT alterations were a result of the gut dysfunction itself. Th is study demonstrates that there are no diff erences in 5-HT content, release, or reuptake in opiate-induced, constipated; opiate non-constipated; or control specimens. Th erefore, the 5-HT alterations measured in this study may suggest a causal relationship in CC. It would be interesting to determine whether the features of mucosal 5-HT signaling return to normal in individuals whose symptoms are successfully managed with pharmacological and / or non-pharmacological therapies.
Concluding remarks
Th e fi ndings from this and other studies demonstrate that various aspects of mucosal 5-HT signaling are altered in disorders involving abnormal intestinal function, raising the question of a cause-and-eff ect relationship between gut function and 5-HT signaling in the gut. 5-HT content and availability in the lamina propria were both increased in subjects with CC when compared with controls. As the same alterations were not demonstrated in patients with OIC, our fi ndings support the contention that altered 5-HT signaling does not occur in response to altered gut function. Rather, it may be specifi c to a phenomenon or epiphenomenon associated with functional disorders.
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Th ese results, demonstrating no change in the density of EC cells in CC, are diff erent from previous reports of alterations in the EC cell population in constipated individuals. El-Salhy et al. ( 15 ) reported that the number of 5-HT-immunoreactive cells per unit area of epithelial cells is lower in colons removed for treatment of slow-transit constipation. On the other hand, others have reported that the average number of EC cells per fi eld is increased in surgical specimens ( 16, 17 ) . One possible explanation for these diff erences is that great care was taken in this study to orient the specimens so that sections were cut perpendicular to the luminal surface and only regions of sections containing full-length colonic glands were quantifi ed. Th is is because EC cells are unevenly distributed in the glands, with more of these cells located at their base. Th e micrographs included in the previous publications indicate that randomly oriented colonic glands were included in those studies, and there is no indication that full-length glands were evaluated. Other possible explanations include the fact that we were looking at the rectum and they were looking at the right and left colon. Furthermore, the previous studies were limited to slow-transit constipation cases that were severe enough to require surgical intervention, whereas this study involved endoscopically obtained rectal biopsies from individuals with intact colons.
It is oft en diffi cult to distinguish CC from IBS-C, and it has been proposed that they actually represent a single condition with patients situated at various points along a pain and discomfort spectrum ( 7 ) . In this study, subjects were excluded if pain and / or discomfort were a predominant symptom. In other words, visceral hypersensitivity was not a common condition in these individuals as it is in IBS-C. Comparison of the results of this study regarding 5-HT signaling in CC with those from studies of IBS-C indicate that while 5-HT is altered in both disorders, the features of these alterations diff er between CC and IBS-C.
Previous studies of 5-HT signaling in IBS-C have yielded somewhat contradictory results. Th e serotonin content in mucosal samples has been reported to be decreased ( 8 ) , increased ( 18 ) , or unchanged ( 19 ) . Th e number of EC cells is unchanged ( 8, 19 ) , and the one study of 5-HT release from mucosal samples failed to detect a diff erence between control and IBS-C samples under basal or stimulated conditions ( 8 ) . Lines of evidence for a decrease in SERT expression include the fi nding that SERT RNA levels are lower in IBS-C samples than controls ( 8 ) , and that platelet 5-HT levels are elevated in IBS-C ( 20 ) , suggesting that less 5-HT is being taken up into epithelial cells, resulting in more 5-HT entering into the bloodstream and being taken up by platelets. However, another study failed to detect a diff erence in SERT RNA levels in control vs. IBS-C mucosal biopsies ( 21 ) .
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
3 Serotonin is an important signaling molecule in the intestines.
3 Serotonin signaling is altered in infl ammatory bowel disease and irritable bowel syndrome.
WHAT IS NEW HERE
3 Serotonin synthesis and release are increased in chronic constipation.
3 Constipation does not lead to compensatory changes in serotonin signaling.
